

# Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/PF993D4FEEFBEN.html>

Date: March 2022

Pages: 163

Price: US\$ 2,000.00 (Single User License)

ID: PF993D4FEEFBEN

## Abstracts

Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pruritus - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Pruritus (Dermatology) pipeline landscape.

Pruritus, or itch, is defined as an unpleasant sensation that provokes the desire to scratch. Pruritus is caused by cancer, cancer treatments, infection, dry skin and reaction to a drug. Symptoms include redness, bumps, spots or blisters, dry, cracked skin and leathery or scaly texture to the skin. Risk factors include heat, allergic, asthma, hay fever, hives and eczema. Treatment includes corticosteroids, antihistamines and antidepressants.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pruritus - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Pruritus (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the

therapeutics, its complete research and development history and latest news and press releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 5, 11, 11, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Pruritus (Dermatology).

The pipeline guide reviews pipeline therapeutics for Pruritus (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Pruritus (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Pruritus (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Pruritus (Dermatology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Pruritus (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Pruritus (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Pruritus - Overview
- Pruritus - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Pruritus - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Pruritus - Companies Involved in Therapeutics Development
- 9 Meters Biopharma Inc
- AfaSci Inc
- Akaal Pharma Pty Ltd
- Albireo Pharma Inc
- Amgen Inc
- AntalGenics SL
- AOBiome LLC
- Asana BioSciences LLC
- Avior Bio Inc
- BioArdis LLC
- Biomimetix JV LLC
- Cara Therapeutics Inc
- Chugai Pharmaceutical Co Ltd
- Clexio Biosciences Ltd
- DermaXon LLC
- DongKoo Bio & Pharma Co Ltd
- ELORAC Inc
- Escient Pharmaceuticals Inc
- Evommune Inc
- Genu Pharma Co Ltd
- GlaxoSmithKline Plc
- Jiangsu Hengrui Medicine Co Ltd

Kiniksa Pharmaceuticals Ltd  
Kissei Pharmaceutical Co Ltd  
Lumosa Therapeutics Co Ltd  
MC2 Therapeutics AS  
Mirum Pharmaceuticals Inc  
Neurim Pharmaceuticals Ltd  
Patagonia Pharmaceuticals LLC  
Peptide Logic LLC  
Pfizer Inc  
RaQualia Pharma Inc  
Regeneron Pharmaceuticals Inc  
Saniona AB  
Sanwa Kagaku Kenkyusho Co Ltd  
Shanton Pharma Co Ltd  
Sichuan Haisco Pharmaceutical Co Ltd  
Sienna Biopharmaceuticals Inc  
Sunny Pharmtech Inc  
Suzhou Connect Biopharmaceuticals Ltd  
Teikoku Pharma USA Inc  
Tioga Pharmaceuticals Inc  
Titan Pharmaceuticals Inc  
Toray Industries Inc  
Trevi Therapeutics Inc  
Vivozon Inc  
YIRUI Pharmaceutical Technology Co Ltd  
Pruritus - Drug Profiles  
abrocitinib - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
AG-1529 - Drug Profile  
Product Description  
Mechanism Of Action  
AKP-11 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
AM-6120 - Drug Profile  
Product Description

Mechanism Of Action  
AMG-8379 - Drug Profile  
Product Description  
Mechanism Of Action  
asimadoline - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
ASN-008 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
ASN-009 - Drug Profile  
Product Description  
Mechanism Of Action  
AV-104 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
B-244 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
bepotastine SR - Drug Profile  
Product Description  
Mechanism Of Action  
BMX-010 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
CBP-174 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
detomidine - Drug Profile  
Product Description  
Mechanism Of Action  
difelikefalin - Drug Profile  
Product Description

Mechanism Of Action  
History of Events  
DKB-19003 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Drugs to Block Cav3 and Nav for Pruritus - Drug Profile  
Product Description  
Mechanism Of Action  
dupilumab - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
DX-412 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
EP-547 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
EVO-103 - Drug Profile  
Product Description  
Mechanism Of Action  
HPI-1201 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
HSK-21542 - Drug Profile  
Product Description  
Mechanism Of Action  
KNV-0969 - Drug Profile  
Product Description  
Mechanism Of Action  
linerixibat - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
LT-5001 - Drug Profile



Product Description  
Mechanism Of Action  
History of Events  
MC-225 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Monoclonal Antibody Conjugate to Agonize Kappa Opioid Receptor for Dermatitis,  
Osteoarthritis Pain and Uremic Pruritus - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
MRGPRX2 Antagonist - Drug Profile  
Product Description  
Mechanism Of Action  
nalbuphine hydrochloride ER - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
nalfurafine hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
naloxone hydrochloride - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
nemolizumab - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
NeuP-12 - Drug Profile  
Product Description  
Mechanism Of Action  
odevixibat - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
opiranserin - Drug Profile

Product Description  
Mechanism Of Action  
PATN-02 - Drug Profile  
Product Description  
Mechanism Of Action  
pegcantratinib - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Peptides to Target TRPV1 for Pain and Pruritus - Drug Profile  
Product Description  
Mechanism Of Action  
phenylbutyrate - Drug Profile  
Product Description  
Mechanism Of Action  
PR-38 - Drug Profile  
Product Description  
Mechanism Of Action  
RDD-1609 - Drug Profile  
Product Description  
Mechanism Of Action  
SAN-711 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
SAP-002 - Drug Profile  
Product Description  
Mechanism Of Action  
SHR-0410 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
SK-1405 - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
Small Molecule to Agonize KOR1 for Pruritus - Drug Profile  
Product Description  
Mechanism Of Action

## Small Molecules to Block Nav1.8 Sodium Channel for Pain And Pruritis - Drug Profile

Product Description

Mechanism Of Action

History of Events

TPU-010 - Drug Profile

Product Description

Mechanism Of Action

vixarelimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

volixibat potassium - Drug Profile

Product Description

Mechanism Of Action

History of Events

YR-007 - Drug Profile

Product Description

Mechanism Of Action

Pruritus - Dormant Projects

Pruritus - Discontinued Products

Pruritus - Product Development Milestones

Featured News & Press Releases

Mar 28, 2022: Cara Therapeutics announces Oral KORSUVA (difelikefalin) improves itch and inflammatory biomarkers in atopic dermatitis patients with moderate-to-severe pruritus

Mar 08, 2022: Cara Therapeutics announces oral KORSUVA (difelikefalin) data selected for late-breaking presentation at 2022 American Academy of Dermatology Annual Meeting

Feb 25, 2022: Kaprivia receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Feb 22, 2022: AOBiome Therapeutics' topical biotherapeutic B244 demonstrated positive Phase 2b results from its 547 patient trial for both Pruritus (Itch) and appearance in its 547 patient Phase 2b trial of Atopic Dermatitis (Eczema)

Feb 02, 2022: Trevi concludes enrolment of Phase IIb/III itch trial in prurigo nodularis

Jan 10, 2022: Cara Therapeutics announces Difelikefalin (KORSUVA) Injection achieves positive topline results in Phase 3 clinical study in Japan for the treatment of pruritus in hemodialysis patients

Jan 10, 2022: Cara Therapeutics announces Difelikefalin (KORSUVA) Injection achieves positive topline results in Phase 3 clinical study in Japan for the treatment of

pruritus in hemodialysis patients

Jan 05, 2022: Enteris BioPharma highlights 2021 achievements and 2022 Outlook

Jan 05, 2022: Albireo increases 2021 Bylvay (odevixibat) sales guidance

Dec 20, 2021: Cara Therapeutics announces CMS grants TDAPA to KORSUVA (difelikefalin) injection

Dec 13, 2021: Albireo presenting new Bylvay (odevixibat) Data at NASPGHAN 2021

Nov 16, 2021: AOBiome achieves landmark recruitment goal in largest clinical trial ever powered by a live topical biotherapeutic

Nov 15, 2021: Trevi Therapeutics to present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases

Nov 12, 2021: Albireo announces new phase 3 data for Bylvay (odevixibat) in PFIC and first reveal of new next generation bile acid modulator data at AASLD The Liver Meeting 2021

Nov 05, 2021: Titan announces upcoming TP-2021 Implant data presentation at Neuroscience 2021

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Pruritus, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Products under Development by Companies, 2022 (Contd..3)  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Target, 2022 (Contd..1)  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Pruritus - Pipeline by 9 Meters Biopharma Inc, 2022  
Pruritus - Pipeline by AfaSci Inc, 2022  
Pruritus - Pipeline by Akaal Pharma Pty Ltd, 2022  
Pruritus - Pipeline by Albireo Pharma Inc, 2022  
Pruritus - Pipeline by Amgen Inc, 2022  
Pruritus - Pipeline by AntalGenics SL, 2022  
Pruritus - Pipeline by AOBiome LLC, 2022  
Pruritus - Pipeline by Asana BioSciences LLC, 2022  
Pruritus - Pipeline by Avior Bio Inc, 2022  
Pruritus - Pipeline by BioArdis LLC, 2022  
Pruritus - Pipeline by Biomimetix JV LLC, 2022  
Pruritus - Pipeline by Cara Therapeutics Inc, 2022  
Pruritus - Pipeline by Chugai Pharmaceutical Co Ltd, 2022  
Pruritus - Pipeline by Clexio Biosciences Ltd, 2022  
Pruritus - Pipeline by DermaXon LLC, 2022  
Pruritus - Pipeline by DongKoo Bio & Pharma Co Ltd, 2022  
Pruritus - Pipeline by ELORAC Inc, 2022  
Pruritus - Pipeline by Escient Pharmaceuticals Inc, 2022  
Pruritus - Pipeline by Evommune Inc, 2022  
Pruritus - Pipeline by Genu Pharma Co Ltd, 2022

Pruritus - Pipeline by GlaxoSmithKline Plc, 2022  
Pruritus - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022  
Pruritus - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022  
Pruritus - Pipeline by Kissei Pharmaceutical Co Ltd, 2022  
Pruritus - Pipeline by Lumosa Therapeutics Co Ltd, 2022  
Pruritus - Pipeline by MC2 Therapeutics AS, 2022  
Pruritus - Pipeline by Mirum Pharmaceuticals Inc, 2022  
Pruritus - Pipeline by Neurim Pharmaceuticals Ltd, 2022  
Pruritus - Pipeline by Patagonia Pharmaceuticals LLC, 2022  
Pruritus - Pipeline by Peptide Logic LLC, 2022  
Pruritus - Pipeline by Pfizer Inc, 2022  
Pruritus - Pipeline by RaQualia Pharma Inc, 2022  
Pruritus - Pipeline by Regeneron Pharmaceuticals Inc, 2022  
Pruritus - Pipeline by Saniona AB, 2022  
Pruritus - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, 2022  
Pruritus - Pipeline by Shanton Pharma Co Ltd, 2022  
Pruritus - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, 2022  
Pruritus - Pipeline by Sienna Biopharmaceuticals Inc, 2022  
Pruritus - Pipeline by Sunny Pharmtech Inc, 2022  
Pruritus - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022  
Pruritus - Pipeline by Teikoku Pharma USA Inc, 2022  
Pruritus - Pipeline by Tioga Pharmaceuticals Inc, 2022  
Pruritus - Pipeline by Titan Pharmaceuticals Inc, 2022  
Pruritus - Pipeline by Toray Industries Inc, 2022  
Pruritus - Pipeline by Trevi Therapeutics Inc, 2022  
Pruritus - Pipeline by Vivozon Inc, 2022  
Pruritus - Pipeline by YIRUI Pharmaceutical Technology Co Ltd, 2022  
Pruritus - Dormant Projects, 2022  
Pruritus - Dormant Projects, 2022 (Contd..1)  
Pruritus - Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Pruritus, 2022  
Number of Products under Development by Companies, 2022  
Number of Products by Top 10 Targets, 2022  
Number of Products by Stage and Top 10 Targets, 2022  
Number of Products by Top 10 Mechanism of Actions, 2022  
Number of Products by Stage and Top 10 Mechanism of Actions, 2022  
Number of Products by Top 10 Routes of Administration, 2022  
Number of Products by Stage and Top 10 Routes of Administration, 2022  
Number of Products by Top 10 Molecule Types, 2022  
Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Pruritus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/PF993D4FEEFBEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PF993D4FEEFBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



